{
    "id": 18774,
    "fullName": "FLT3 D835F",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FLT3 D835F lies within the activation loop in the protein kinase domain of the Flt3 protein (PMID: 25837374). D835F has been associated with acquired resistance to sorafenib (PMID: 24227820), but has not been biochemically characterized and therefore, its effect on Flt3 protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 14183,
                    "pubMedId": 25837374,
                    "title": "Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25837374"
                },
                {
                    "id": 2134,
                    "pubMedId": 24227820,
                    "title": "Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24227820"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2322,
        "geneSymbol": "FLT3",
        "terms": [
            "FLT3",
            "CD135",
            "FLK-2",
            "FLK2",
            "STK1"
        ]
    },
    "variant": "D835F",
    "createDate": "02/28/2016",
    "updateDate": "03/16/2020",
    "referenceTranscriptCoordinates": {
        "id": 144447,
        "transcript": "NM_004119",
        "gDna": "chr13:g.28018504_28018505delTCinsAA",
        "cDna": "c.2503_2504delGAinsTT",
        "protein": "p.D835F",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9438,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and D835F in culture (PMID: 27158668).",
            "molecularProfile": {
                "id": 19133,
                "profileName": "FLT3 exon 14 ins FLT3 D835F"
            },
            "therapy": {
                "id": 5016,
                "therapyName": "MRX-2843",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7187,
                    "pubMedId": 27158668,
                    "title": "The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27158668"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15035,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, FLT3 D835F was identified as an acquired resistance mutation in a patient with acute myeloid leukemia harboring a FLT3 internal tandem duplication (ITD) whose disease progressed on Nexavar (sorafenib) after initial response (PMID: 24227820).",
            "molecularProfile": {
                "id": 19133,
                "profileName": "FLT3 exon 14 ins FLT3 D835F"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 2134,
                    "pubMedId": 24227820,
                    "title": "Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24227820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4795,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FLT3-ITD along with FLT3 D835F were resistant to PLX3397 in culture (PMID: 25847190).",
            "molecularProfile": {
                "id": 19133,
                "profileName": "FLT3 exon 14 ins FLT3 D835F"
            },
            "therapy": {
                "id": 874,
                "therapyName": "Pexidartinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3027,
                    "pubMedId": 25847190,
                    "title": "Characterizing and Overriding the Structural Mechanism of the Quizartinib-Resistant FLT3 \"Gatekeeper\" F691L Mutation with PLX3397.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25847190"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15036,
            "approvalStatus": "Preclinical - Patient cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Crenolanib inhibited growth of blasts derived from a patient with acute myeloid leukemia harboring FLT3 internal tandem duplication (ITD) and FLT3 D835F (PMID: 24227820).",
            "molecularProfile": {
                "id": 19133,
                "profileName": "FLT3 exon 14 ins FLT3 D835F"
            },
            "therapy": {
                "id": 705,
                "therapyName": "Crenolanib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2134,
                    "pubMedId": 24227820,
                    "title": "Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24227820"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 19132,
            "profileName": "FLT3 D835F",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 19133,
            "profileName": "FLT3 exon 14 ins FLT3 D835F",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 144447,
            "transcript": "NM_004119",
            "gDna": "chr13:g.28018504_28018505delTCinsAA",
            "cDna": "c.2503_2504delGAinsTT",
            "protein": "p.D835F",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}